Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pulmonary Vascular Disease (week 5) > Pharmacology of Anticoagulants > Flashcards

Pharmacology of Anticoagulants Flashcards

1. Describe the pharmacodynamics, pharmacokinetics, adverse effects and indications of/for heparin (unfractionated and low molecular weight) 2. Describe the pharmacodynamics, pharmacokinetics, adverse effects, drug interactions and indications of/for warfarin and the newer oral anticoagulants 3. Describe the mechanism of action, adverse effects and indications of/for thrombolytic agents

1
Q

How clots form

A
  1. Vessel damage
  2. Platelets adhere to site of injury
  3. Activation of clotting cascade n activated platelet surface by tissue factor (factor VIIa)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Fibrin clot formation - function of fibrin deposition

A

Fibrin deposition stabilizes the platelet thrombus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Targets for anti-coagulation

A
  1. Anti-platelet agents
  2. Chelate calcium ions
  3. Inhibit liver carboxylation of Gla proteins
  4. Accelerate inhibition of thrombin and factor Xa by antithrombin
  5. Directly inhibit thrombin and factor Xa
  6. Thrombolytic agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anti-platelet agents

A

Asprin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Chelate calcium ions

A
  • citrate

- EDTA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Inhibit liver carboxylation of Gla proteins

A

-coumarol drugs such as coumadin and warfarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Drugs that accelerate inhibition of thrombin and factor Xa by antithrombin

A

Heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Drugs that directly inhibit thrombin and factor Xa

A

New oral anticoagulants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Drugs that are thrombolytic agents

A

tPA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MOA of asprin

A

1) Inhibits platelet cyclo-oxygenase by acetylation
2) Prevents synthesis of thromboxane A2
3) Stops thromboxane A2 -induced platelet activation and aggregation thereby reducing platelet plug formation at early stage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Calcium chelators MOA

A
  • i.e. metal chelators such as citrate and EDTA
    1) Strip Ca2+ from Gla proteins
    2) Non-Ca2_ Gla proteins cannot bind to phospholipids
    3) Reversed by adding excess Ca2+
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Coumarol drugs MOA

A

1) inhibit reduction of vitamin K in the liver
2) Vitamin K becomes limiting and Gla-less proteins made by liver (inhibit liver carboxylation of Gla proteins: prothrombin, factor IX, factor X, factor VII, protein C, protein S)
3) Gla-less proteins do not bind Ca2+ so no conformational change
4) Gla-less proteins cannot bind to membrane at the site of injury
5) Clotting inhibited until coumarol is replaced by vitamin K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

History coumarol drugs

A
  • dicoumarol discovered when cows bled after eating sweet clover
  • warfarin is a synthetic version
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Warfarin bioavailability

A

Well absorbed orally (100% bioavailability)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Warfarin onset

A

-delayed onset of anticoagulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Surmounting warfarin

A

Surmountably antagonized by vitamin K

Can have its effect altered by diet (broccoli)

17
Q

Warfarin solubility

A

Highly (99%) plasma protein bound - fat soluble vitamin

18
Q

net effect of warfarin

A

Prolong prothrombin time

19
Q

Indications for warfarin (6)

A
  1. Prophylaxis and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism)
  2. Prophylaxis and treatment of atrial fibrillation
  3. Valvular stenosis
  4. Heart valve replacement
  5. Myocardial infarction
  6. Antiphospholipid syndrome
20
Q

Contraindications and precautions

A
  1. Hypersensitivity to warfarin
  2. Condition with risk of hemorrhage
  3. Hemorrhagic tendency
  4. Inadequate laboratory techniques
  5. Vitamin K deficiency
  6. Intramuscular injections
  7. Non-steroidal anti-inflammatory drugs (asprin)
21
Q

Side effects of warfarin

A
  1. Hemorrhage
  2. Skin necrosis
  3. Purple toe syndrome
  4. Microembolism
  5. Teratogenecity
  6. Agranulocytosis
  7. Leukopenia
  8. Diarrhea
  9. Nausea
  10. Anorexia
22
Q

Factors influencing dose response

A
  1. Inaccurate laboratory testing
  2. Poor patient compliance
  3. Concomitant medications
    (drug interactions)
  4. Levels of dietary vitamin K
  5. Alcohol
  6. Hepatic dysfunction
23
Q

Why monitor warfarin therapy

A
  1. Narrow therapeutic range

2. Increased risk of bleeding

24
Q

How to monitor warfarin therapy

A

-measure PT and INR from drop of blood (hand-held devices)

25
Q

Composition of heparin

A

-polysaccharide composed of mixed polymers of sulfated sugars (glucosamine, iduronate, glucuronate)

26
Q

Charge of heparin

A

Very negatively charged

27
Q

Heparin MOA

A

1) Contains binding sites for antithrombin and thrombin/factor Xa
- antithrombin = serine protease inhibitor (serpin)
2) Cleaved antithrombin undergoes a conformation change = mousetrap inhibitor
3) Mouse trap inhibitor wraps round a protease and renders the thrombin inactive
4) thrombin or factor Xa is rendered inactive

AT + H AT:H (activated complex) – (thrombin factor Xa)–> AT:E + H (covalent complex between thrombin an antithrombin = inactive)

28
Q

Variability in function of thrombins based on size

A
  • any size of heparin chain can accelerate the inhibition of factor Xa by antithrombin
  • only heparin chains > 18 sugars can accelerate the inhibition of thrombin by antithrombin (heparin must bind to AT and thrombin)
29
Q

Advantages of LMWH over UH

A

1) Decreased heparin resistance
2) No need for laboratory monitoring
3) Higher bioavailability (90% vs 30%)
4) Longer plasma half life (4-6 hrs versus 0.5 to 1 hr)
5) Less inhibition of platelet function
6) Lower incidence of thrombcytopenia and thrombosis
7) Antibodies can be formed against a heparin-platelet factor 4 complex - these platelets can ativate platelets leading to thrombosis and platelet consumption (less interact of LMWH with platelet factor 4 so less chance of heparin-dependent IgG antibodies)

30
Q

Decreased heparin resistance with LMWH vs UH why?

A

Pharmacokinetics of UH are influenced by binding of plasma proteins, endothelial cell surface, macrophages an acute phase reactants
-LMWH has decreased binding to non anticoagulant related proteins

31
Q

Why no need for laboratory monitoring

A

When given on weight -adjusted bases LMWH response is predictable and reproducible

32
Q

How to reverse the effects of heparin

A

Effects may be reversed by protamine sulfate (a polycationic protein that complexes with heparin)

33
Q

Immediate effect of heparin

A

Causes immediate anticoagulation

34
Q

Worst side effects of heparin

A

May cause fatal thrombocytopenia

35
Q

Direct inhibition of thrombin and factor Xa MOA

A

Computer-designed small molecule inhibitors
Bind tightly to active site of proteases
a) Rivaroxaban - inhibits factor Xa
b) Dabigatran - inhibits thrombin

36
Q

Advantage/disadvantage of direct inhibition of thrombin and factor Xa

A
  • Advantage: do not require continuous monitoring of clotting time
  • Disadvantage = no current antidote
37
Q

Thrombolytic agents MOA

A

-activate plasminogen to plasmin

38
Q

Example of thrombolytic agents

A

1) Tissue plasminogen activator
2) Urokinase
3) Streptokinase (bacterial)

39
Q

Use of thrombolytic agents

A

Used for ischemic stroke (caused by blood clot)

Pulmonary Vascular Disease (week 5) (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions